Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis

References

• Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5(6):618–625.
   PubMed Web of Science ®Google Scholar
• Bonnet N, Bourgoin L, Biver E, et al. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019;129(8):3214–3223.
   PubMed Web of Science ®Google Scholar
• Wilson C. Diabetes: Blocking RANKL signalling might prevent T2DM. Nat Rev Endocrinol. 2013;9(4):188.
   PubMedGoogle Scholar
• Weivoda MM, Chew CK, Monroe DG, et al. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat Commun. 2020;11(1):87.
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–150.
   PubMed Web of Science ®Google Scholar
• Huang R, Wang X, Zhou Y, et al. RANKL-induced M1 macrophages are involved in bone formation. Bone Res. 2017; 5(1):17019.
   PubMedGoogle Scholar
• Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013;19(3):358–363.
   PubMed Web of Science ®Google Scholar
• Atak B, Aktas G, Duman TT, et al. Diabetes control could through platelet-to-lymphocyte ratio in hemograms. Rev Assoc Med Bras. 2019;65(1):38–42.
   PubMed Web of Science ®Google Scholar
• Duman TT, Aktas G, Atak BM, et al. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci. 2019;19(1):1602–1606.
   PubMed Web of Science ®Google Scholar
• Bilgin S, Aktas G, Zahid Kocak M, et al. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2020;23(5):923–927.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang C, Hu Y, et al. Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin. J Endod. 2012;38(7):943–947.
   PubMed Web of Science ®Google Scholar
• Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011;112(10):2902–2909.
   PubMed Web of Science ®Google Scholar
• Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196–205.
   PubMed Web of Science ®Google Scholar
• Duan P, Yang M, Wei M, et al. Serum osteoprotegerin is a potential biomarker of insulin resistance in Chinese postmenopausal women with prediabetes and type 2 diabetes. Int J Endocrinol. 2017;2017:1–8.
   Web of Science ®Google Scholar
• Cantley J, Ashcroft FQA. Insulin secretion and type 2 diabetes: why do β-cells fail?. BMC Biol. 2015;13:33.
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute charcot foot) in diabetes. Lancet. 2005;366(9502):2058–2061.
   PubMed Web of Science ®Google Scholar
• Dahiya N, Khadka A, Sharma AK, et al. Denosumab: a bone antiresorptive drug. Med J Armed Forces India. 2015;71(1):71–75.
   PubMedGoogle Scholar
• Mohsin S, Baniyas MM, AlDarmaki RS, et al. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019;19(9):937–948.
   PubMed Web of Science ®Google Scholar
• Abe I, Ochi K, Takashi Y, et al. Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: effect of denosumab on glycemic parameters. Medicine. 2019;98(47):e18067.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Schafer AL, Grey A, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res. 2013;28(6):1348–1354.
   PubMed Web of Science ®Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.
   PubMed Web of Science ®Google Scholar
• Hooper P, Jutai JW, Strong G, et al. Age-related macular degeneration and low-vision rehabilitation: a systematic review. Can J Ophthalmol. 2008;43(2):180–187.
   PubMed Web of Science ®Google Scholar
• Sacks DB. Measurement of hemoglobin A(1c): a new twist on the path to harmony. Diabetes Care. 2012;35(12):2674–2680.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 2011 [updated 2011 Mar; cited 2020 Dec 10]. Available from: https://handbook-5-1.cochrane.org/.
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Lasco A, Morabito N, Basile G, et al. Denosumab inhibition of RANKL and insulin resistance in postmenopausal women with osteoporosis. Calcif Tissue Int. 2016;98(2):123–128.
   PubMed Web of Science ®Google Scholar
• Passeri E, Benedini S, Costa E, et al. A single 60 mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal nondiabetic severe osteoporotic women. Int J Endocrinol. 2015;2015:352858.
   PubMed Web of Science ®Google Scholar
• Rossini A, Frigerio S, Dozio E, et al. Effect of denosumab on glucose homeostasis in postmenopausal women with breast cancer treated with aromatase inhibitors: a pilot Study. Int J Endocrinol. 2020;2020:1809150.
   PubMed Web of Science ®Google Scholar
• Napoli N, Pannacciulli N, Vittinghoff E, et al. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab Res Rev. 2018;34(4):e2991.
   PubMed Web of Science ®Google Scholar
• Chung PL, Zhou S, Eslami B, et al. Effect of age on regulation of human osteoclast differentiation. J Cell Biochem. 2014;115(8):1412–1419.
   PubMed Web of Science ®Google Scholar
• Naumnik B, Klejna K, Koc-Żórawska E, et al. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients. Adv Med Sci. 2013;58(2):382–387.
   PubMed Web of Science ®Google Scholar
• de Paula FJ, Horowitz MC, Rosen CJ. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev. 2010;26(8):622–630.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar D, Lal AK. Serum osteocalcin as a diagnostic biomarker for primary osteoporosis in Women. J Clin Diagn Res. 2015; 9(8):RC04–RC07.
   PubMed Web of Science ®Google Scholar
• Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009;5(7):365–372.
   PubMed Web of Science ®Google Scholar
• Buch K, Gunmalm V, Andersson M, et al. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism–a systematic review. Cancer Med. 2019;8(1):238–245.
   PubMed Web of Science ®Google Scholar
• Mirhosseini N, Vatanparast H, Mazidi M, et al. Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis. J Endocr Soc. 2018;2(7):687–709.
   PubMed Web of Science ®Google Scholar
• Yousefi Rad E, Djalali M, Koohdani F, et al. The effects of vitamin D supplementation on glucose control and insulin resistance in patients with diabetes type 2: a randomized clinical trial study. Iran J Public Health. 2014;43(12):1651–1656.
   PubMed Web of Science ®Google Scholar
• Chaudhury A, Duvoor CR, Dendi VS, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Baldock PA, Thomas GP, Hodge JM, et al. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006;21(10):1618–1626.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Suzuki T, Kamimura M, et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res. 2017;5(1):e17021.
   PubMedGoogle Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593.
   PubMed Web of Science ®Google Scholar
• Lim S, Ku EJ, Lee SY, et al. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Res Care. 2020;8(1):e000807.
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.
   PubMed Web of Science ®Google Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12(2):153–175.
   PubMed Web of Science ®Google Scholar
• Weir GC, Bonner-Weir S. Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci. 2013;1281(1):92–105.
   PubMedGoogle Scholar
• Kondegowda NG, Fenutria R, Pollack IR, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway. Cell Metab. 2015;22(1):77–85.
   PubMed Web of Science ®Google Scholar
• Cunha JS, Ferreira VM, Maquigussa E, et al. Effects of high glucose and high insulin concentrations on osteoblast function in vitro. Cell Tissue Res. 2014;358(1):249–256.
   PubMed Web of Science ®Google Scholar
• Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016;27(3):367–375.
   PubMed Web of Science ®Google Scholar
• Poudel P, Griffiths R, Wong VW, et al. Oral health knowledge, attitudes and care practices of people with diabetes: a systematic review. BMC Public Health. 2018;18(1):577.
   PubMedGoogle Scholar
• Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35(2):163–173.
   PubMed Web of Science ®Google Scholar
• Li N, Cornelissen D, Silverman S, et al. An updated systematic review of Cost-Effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39(2):181–209.
   PubMed Web of Science ®Google Scholar
• John M. Medicines for type 2 diabetes: a review of the research for adults. In: Comparative effectiveness review summary guides for clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 [cited 2021 Aug 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK63537/
   Google Scholar